The Application of Hollow Fiber Cartridge in Biomedicine

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Jul 27

PMID 35890380

Authors

Yixuan Hou

Kun Mi

Lei Sun

Kaixiang Zhou

Lei Wang

Lan Zhang

Zhenli Liu

Lingli Huang

Affiliations

Soon will be listed here.

Abstract

The hollow fiber cartridge has the advantages of good semi-permeability, high surface area to volume ratio, convenient operation, and so on. Its application in chemical analysis, drug in vitro experiment, hemodialysis, and other fields has been deeply studied. This paper introduces the basic structure of hollow fiber cartridge, compares the advantages and disadvantages of a hollow fiber infection model constructed by a hollow fiber cartridge with traditional static model and animal infection model and introduces its application in drug effects, mechanism of drug resistance, and evaluation of combined drug regimen. The principle and application of hollow fiber bioreactors for cell culture and hollow fiber dialyzer for dialysis and filtration were discussed. The hollow fiber cartridge, whether used in drug experiments, artificial liver, artificial kidney, etc., has achieved controllable experimental operation and efficient and accurate experimental results, and will provide more convenience and support for drug development and clinical research in the future.

Citing Articles

Hollow Fiber Microreactor Combined with Digital Twin to Optimize the Antimicrobial Evaluation Process.

Noda K, Kasama T, Shinohara M, Hamada M, Matsunaga Y, Takai M Micromachines (Basel). 2025; 15(12.

PMID: 39770270 PMC: 11677925. DOI: 10.3390/mi15121517.

Dynamic PK/PD Infection Models for the Development and Optimisation of Antimicrobial Regimens: A Narrative Review.

Wale Y, Roberts J, Sime F Antibiotics (Basel). 2025; 13(12.

PMID: 39766591 PMC: 11672834. DOI: 10.3390/antibiotics13121201.

Engineering cell-derived extracellular matrix for peripheral nerve regeneration.

Xu Y, Liu X, Ahmad M, Ao Q, Yu Y, Shao D Mater Today Bio. 2024; 27:101125.

PMID: 38979129 PMC: 11228803. DOI: 10.1016/j.mtbio.2024.101125.

Extracellular Vesicles as Next-Generation Diagnostics and Advanced Therapy Medicinal Products.

Stawarska A, Bamburowicz-Klimkowska M, Runden-Pran E, Dusinska M, Cimpan M, Rios-Mondragon I Int J Mol Sci. 2024; 25(12).

PMID: 38928240 PMC: 11204223. DOI: 10.3390/ijms25126533.

Chromatography affinity resin with photosynthetically-sourced protein A ligand.

Owens N, Anborgh P, Kolotilin I Sci Rep. 2024; 14(1):8714.

PMID: 38622266 PMC: 11018848. DOI: 10.1038/s41598-024-59266-2.

References

Roberts J, Abdul-Aziz M, Lipman J, Mouton J, Vinks A, Felton T . Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014; 14(6):498-509. PMC: 4181663. DOI: 10.1016/S1473-3099(14)70036-2. View

Alm R, Lahiri S, Kutschke A, Otterson L, McLaughlin R, Whiteaker J . Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2014; 59(3):1478-86. PMC: 4325766. DOI: 10.1128/AAC.04456-14. View

Watson D, Bayik D, Srivatsan A, Bergamaschi C, Valentin A, Niu G . Efficient production and enhanced tumor delivery of engineered extracellular vesicles. Biomaterials. 2016; 105:195-205. PMC: 7156278. DOI: 10.1016/j.biomaterials.2016.07.003. View

Grasso S, Meinardi G, DE CARNERI I, Tamassia V . New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother. 1978; 13(4):570-6. PMC: 352290. DOI: 10.1128/AAC.13.4.570. View

Deshpande D, Pasipanodya J, Mpagama S, Bendet P, Srivastava S, Koeuth T . Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. Clin Infect Dis. 2018; 67(suppl_3):S293-S302. PMC: 6260169. DOI: 10.1093/cid/ciy611. View

Yehl C, Jabra M, Zydney A . Hollow fiber countercurrent dialysis for continuous buffer exchange of high-value biotherapeutics. Biotechnol Prog. 2018; 35(2):e2763. DOI: 10.1002/btpr.2763. View

Garimella N, Zere T, Hartman N, Gandhi A, Bekele A, Li X . Effect of drug combinations on the kinetics of antibiotic resistance emergence in Escherichia coli CFT073 using an in vitro hollow-fibre infection model. Int J Antimicrob Agents. 2019; 55(4):105861. DOI: 10.1016/j.ijantimicag.2019.105861. View

Cavaleri M, Manolis E . Hollow Fiber System Model for Tuberculosis: The European Medicines Agency Experience. Clin Infect Dis. 2015; 61 Suppl 1:S1-4. DOI: 10.1093/cid/civ484. View

Modi A, Verma S, Bellare J . Extracellular matrix-coated polyethersulfone-TPGS hollow fiber membranes showing improved biocompatibility and uremic toxins removal for bioartificial kidney application. Colloids Surf B Biointerfaces. 2018; 167:457-467. DOI: 10.1016/j.colsurfb.2018.04.043. View

10.

Booker B, Smith P, Forrest A, Bullock J, Kelchlin P, Bhavnani S . Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother. 2005; 49(5):1775-81. PMC: 1087614. DOI: 10.1128/AAC.49.5.1775-1781.2005. View

11.

Zhao L, Li X, He X, Jian L . Levofloxacin-ceftazidime administration regimens combat Pseudomonas aeruginosa in the hollow-fiber infection model simulating abnormal renal function in critically ill patients. BMC Pharmacol Toxicol. 2020; 21(1):20. PMC: 7057547. DOI: 10.1186/s40360-020-0396-5. View

12.

Jacobsson S, Golparian D, Oxelbark J, Alirol E, Franceschi F, Gustafsson T . Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against in a Dynamic Hollow Fiber Infection Model. Front Pharmacol. 2021; 12:682135. PMC: 8175963. DOI: 10.3389/fphar.2021.682135. View

13.

Weeraphan C, Diskul-Na-Ayudthaya P, Chiablaem K, Khongmanee A, Chokchaichamnankit D, Subhasitanont P . Effective enrichment of cholangiocarcinoma secretomes using the hollow fiber bioreactor culture system. Talanta. 2012; 99:294-301. DOI: 10.1016/j.talanta.2012.05.054. View

14.

Bonapace C, Friedrich L, Bosso J, White R . Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection. Antimicrob Agents Chemother. 2002; 46(11):3574-9. PMC: 128701. DOI: 10.1128/AAC.46.11.3574-3579.2002. View

15.

Eghbali H, Nava M, Mohebbi-Kalhori D, Raimondi M . Hollow fiber bioreactor technology for tissue engineering applications. Int J Artif Organs. 2016; 39(1):1-15. DOI: 10.5301/ijao.5000466. View

16.

Savarimuthu S, BinSaeid J, Harky A . The role of ECMO in COVID-19: Can it provide rescue therapy in those who are critically ill?. J Card Surg. 2020; 35(6):1298-1301. PMC: 7280692. DOI: 10.1111/jocs.14635. View

17.

Abdul-Aziz M, Lipman J, Mouton J, Hope W, Roberts J . Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med. 2015; 36(1):136-53. DOI: 10.1055/s-0034-1398490. View

18.

Vymetalova L, Kucirkova T, Knopfova L, Pospisilova V, Kasko T, Lejdarova H . Large-Scale Automated Hollow-Fiber Bioreactor Expansion of Umbilical Cord-Derived Human Mesenchymal Stromal Cells for Neurological Disorders. Neurochem Res. 2019; 45(1):204-214. DOI: 10.1007/s11064-019-02925-y. View

19.

Vermasvuori R, Hurme M . Economic comparison of diagnostic antibody production in perfusion stirred tank and in hollow fiber bioreactor processes. Biotechnol Prog. 2011; 27(6):1588-98. DOI: 10.1002/btpr.676. View

20.

Andes D, Craig W . Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother. 2002; 46(6):1665-70. PMC: 127205. DOI: 10.1128/AAC.46.6.1665-1670.2002. View